Literature DB >> 26803634

Toll-Like Receptor-Dependent Immune Complex Activation of B Cells and Dendritic Cells.

Krishna L Moody1, Melissa B Uccellini2, Ana M Avalos1, Ann Marshak-Rothstein3, Gregory A Viglianti4.   

Abstract

High titers of autoantibodies reactive with DNA/RNA molecular complexes are characteristic of autoimmune disorders such as systemic lupus erythematosus (SLE). In vitro and in vivo studies have implicated the endosomal Toll-like receptor 9 (TLR9) and Toll-like receptor 7 (TLR7) in the activation of the corresponding autoantibody producing B cells. Importantly, TLR9/TLR7-deficiency results in the inability of autoreactive B cells to proliferate in response to DNA/RNA-associated autoantigens in vitro, and in marked changes in the autoantibody repertoire of autoimmune-prone mice. Uptake of DNA/RNA-associated autoantigen immune complexes (ICs) also leads to activation of dendritic cells (DCs) through TLR9 and TLR7. The initial studies from our lab involved ICs formed by a mixture of autoantibodies and cell debris released from dying cells in culture. To better understand the nature of the mammalian ligands that can effectively activate TLR7 and TLR9, we have developed a methodology for preparing ICs containing defined DNA fragments that recapitulate the immunostimulatory activity of the previous "black box" ICs. As the endosomal TLR7 and TLR9 function optimally from intracellular acidic compartments, we developed a facile methodology to monitor the trafficking of defined DNA ICs by flow cytometry and confocal microscopy. These reagents reveal an important role for nucleic acid sequence, even when the ligand is mammalian DNA and will help illuminate the role of IC trafficking in the response.

Entities:  

Keywords:  AM14 transgenic BCR; Autoantibodies; B cells; Biotinylated DNA; Endogenous ligands; Flt3L-DCs; IFNα; Immune complex; Rheumatoid factor B cell; TLR7; TLR9

Mesh:

Substances:

Year:  2016        PMID: 26803634     DOI: 10.1007/978-1-4939-3335-8_16

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  6 in total

Review 1.  Antimalarials - old drugs are new again.

Authors:  Anna Woźniacka
Journal:  Postepy Dermatol Alergol       Date:  2021-08-11       Impact factor: 1.664

2.  Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus.

Authors:  Ying Liu; Feng Zhan; Xiao Zhang; Shudian Lin
Journal:  Exp Ther Med       Date:  2017-10-31       Impact factor: 2.447

Review 3.  Pathways leading to an immunological disease: systemic lupus erythematosus.

Authors:  Olga Zharkova; Teja Celhar; Petra D Cravens; Anne B Satterthwaite; Anna-Marie Fairhurst; Laurie S Davis
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

Review 4.  Synergistic Activation of Toll-Like and NOD Receptors by Complementary Antigens as Facilitators of Autoimmune Disease: Review, Model and Novel Predictions.

Authors:  Robert Root-Bernstein
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

5.  AMP5A modulates Toll-like receptors 7 and 8 single-stranded RNA immune responses in PMA-differentiated THP-1 and PBMC.

Authors:  Gregory Thomas; Kristen Hirter; Elizabeth Frederick; Melissa Hausburg; Raphael Bar-Or; Yetti Mulugeta; Michael Roshon; Charles Mains; David Bar-Or
Journal:  Transl Med Commun       Date:  2022-03-03

6.  Prevalence of Pruritus in Cutaneous Lupus Erythematosus: Brief Report of a Multicenter, Multinational Cross-Sectional Study.

Authors:  Dominik Samotij; Justyna Szczęch; Carolyn J Kushner; Mohammad Rafiqul Mowla; Aleksandra Dańczak-Pazdrowska; Emiliano Antiga; François Chasset; Fukumi Furukawa; Minoru Hasegawa; Hideo Hashizume; Aminul Islam; Takaharu Ikeda; Aleksandra Lesiak; Adriana Polańska; Laurent Misery; Jacek C Szepietowski; Daisuke Tsuruta; Zygmunt Adamski; Victoria P Werth; Adam Reich
Journal:  Biomed Res Int       Date:  2018-07-25       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.